Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis
Ночной контроль глюкозы с помощью искусственной поджелудочной железы MD-Logic в домашних условиях: однослепое рандомизированное перекрёстное исследование — промежуточный анализ
2013-08-15
SCID: 54.1/5ytq835u
Discuss with AI
MD-Logic artificial pancreasclosed-loop insulin deliverynocturnal hypoglycemiarandomized crossover trialsensor-augmented pump therapy
Figures from the paper
Abstract (AI)
BACKGROUND: Artificial pancreas (AP) systems have shown an improvement in glucose control and a reduced risk of nocturnal hypoglycemia under controlled conditions but remain to be evaluated under daily-life conditions. OBJECTIVE: To assess the feasibility, safety, and efficacy of the MD-Logic AP in controlling nocturnal glucose levels in the patient's home. METHODS: Two-arm study, each covering four consecutive nights comparing the MD-Logic AP ('closed-loop' arm) with sensor-augmented pump therapy ('control' arm). Fifteen patients (mean age 19 ± 10.4 yr, A1c 7.5 ± 0.5% or 58 ± 5.9 mmol/mol, diabetes duration 9.9 ± 8.2 yr) were randomly assigned either to 'Group A' (first 'closed-loop', then 'control' arm) or to 'Group B' (vice versa). Investigators were masked to treatment intervention. Primary endpoints were the time spent with glucose levels below 70 mg/dL and the percentage of nights in which the mean overnight glucose levels were within 90-140 mg/dL. Endpoint analyses were based on unmodified sensor glucose readings of the four study nights. RESULTS: Time of glucose levels spent below 70 mg/dL was significantly shorter on the closed-loop nights than on control nights, median and interquartile range 3.8 (0, 11.6) and 48.7 (0.6, 67.9) min, respectively; p = 0.0034. The percentage of individual nights in which mean overnight glucose level was within 90-140 mg/dL was 67 (33, 88), and 50 (25, 75), under closed-loop and control nights, respectively, with no statistical difference. Secondary endpoint analyses demonstrated significant improvements in hypoglycemia parameters. No serious adverse events were reported. CONCLUSION: This interim analysis demonstrates the feasibility, safety, and efficiency of the MD-Logic AP system in home use, and demonstrates an improvement over sensor-augmented pump therapy. (ClinicalTrials.gov identifier NCT01726829).
Key Findings
1
A randomized crossover home trial evaluated the MD-Logic artificial pancreas against sensor-augmented pump therapy across four nights per treatment.
2
Closed-loop therapy significantly reduced time spent below 70 mg/dL: median 3.8 versus 48.7 minutes with control therapy (p=0.0034).
3
Mean overnight glucose was within 90–140 mg/dL on 67% of closed-loop nights versus 50% of control nights, without statistical significance.
4
Secondary analyses showed significant improvements in hypoglycemia-related parameters with the MD-Logic system.
5
The interim analysis found home use feasible and safe, with no serious adverse events reported.
Research Object
MD-Logic artificial pancreas system used for nocturnal glucose control in patients with diabetes in the home setting
Research Subject
Feasibility, safety, efficacy, and nocturnal glycemic-control performance, particularly hypoglycemia reduction and maintenance of overnight glucose within the target range
Publication Details
Publication Date
2013-08-15
Journal
Publisher
ISSN
Cited by
108
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest